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Abstract
Background: A number of studies have previously shown that the over expression of different
ribosomal proteins might play an important role in cancer (i.e. S3a, L10, L16). We have previously
reported that RPS2, a 33 Kda ribosomal protein was over expressed in malignant prostate cancer
cell lines and in archived tumor specimens. Thus, RPS2 or other aberrantly over-expressed
ribosomal proteins might promote cancer and be excellent therapeutic targets for treatment of the
disease.
Methods: Western blotting and RT-PCR have been used to measure and compare the levels of
expression of RPS2 in a variety of malignant prostate cancer cell lines, plus normal and benign cells
lines. We have developed a 'ribozyme-like' DNAZYM-1P '10–23' motif oligonucleotide and
examined whether it targets RPS2 in different cell lines by RT-PCR and Western blots. Growth and
apoptosis assays were carried out to measure whether DNAZYM-1P 'knock-down' of RPS2
influenced cell proliferation or survival. We have also developed a SCID mouse tumor model with
PC-3ML cells to determine whether DNAZYM-1P targeting of RPS2 compromised tumor growth
and mouse survival rates in vivo.
Results:  Western blots showed that PC-3ML, LNCaP, CPTX-1532, and pBABE-cmyc stably
transfected IBC-10a cells all over-expressed RPS2, whereas IBC-10a parent, NPTX-1532, and BPH-
1 cells or mouse NIH-3T3 cells expressed barely detectable levels of RPS2. RT-PCR assays showed
that DNAZYM-1P, which targeted RPS2, 'knocked-down' RPS2 expression in the malignant cells
(i.e. PC-3ML cells) in vitro. The DNAZYM-1P also inhibited cell growth and induced apoptosis in
the malignant prostate cells, but had little effect on the normal IBC-10a or NPTX-1532 cell lines.
Finally, SCID mouse tumor modeling studies showed that DNAZYM-1P blocked tumor growth and
metastasis by PC-3ML cells and eventually eradicated tumors following localized or systemic i.v.
delivery. Mouse survival studies revealed that there was a dosage dependent increase in disease
free survival rates in mice treated systemically with DNAZYM-1P (i.e. mouse survival increased
from 0% to 100%).
Conclusion: In sum, we have shown for the first time that therapeutic targeting of RPS2 is an
excellent approach for the eradication of prostate cancer in preclinical tumor modeling studies.
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Background
Although our understanding of their role in cancer is lim-
ited, the expression of a variety of ribosomal proteins has
been associated with the development of prostate and
colon cancer. For example, we have previously reported
that RPS2, a 33 Kda ribosomal protein was over expressed
in malignant prostate cancer cell lines and in archived
tumor specimens [1]. Vaarala et al. [2] found that L7a and
L37 ribosomal proteins were over-expressed in prostate-
cancer cell lines and in prostate cancer tissue samples. Fur-
thermore, L23a- and S14-transcript levels were signifi-
cantly elevated in PC-3 cells as compared to a normal
prostate epithelial cell line termed PrEC [2]. Utilizing
'micro-quantity differential display', Bee et al. [3] found
L19 (RPL19) was 5-fold higher in malignant prostate cell
lines and 8-fold higher in malignant tissues, when com-
pared with their benign counterparts of human prostate
[3]. The authors suggested that expression of RPL19 pro-
tein could be a valuable marker in prostate cancer diagno-
sis and patient management. Similarly, Pogue-Geile et al.
[4] found that the RPS3, RPS6, RPS8, RPS12, RPL5, and
PO ribosomal proteins were expressed at higher levels in
8 different colon adenocarcinomas and adenomatous
polyps. These results suggest that a select pool of ribos-
omal proteins might be elevated in prostate and colon
cancer during the transformation process and play a key
role in tumorigenesis.
Previously, we have cloned a mutant variant of the RPS2
ribosomal protein, termed PCADM-1, and shown that
RPS2 was over expressed in malignant prostate cell lines
and in human prostate cancer (PCa) [1]. PCADM-1 was
over-expressed in human PCa and not found in benign
(BPH), high grade prostatic intraepithelial neoplasia
(HGPIN), or seminal vesicle (SV) tissue. Likewise, the
normal RPS2 gene was found to be over-expressed by
malignant prostate lines (i.e. PC-3 ML and LNCaP cells),
and by early stage prostate cancer cell lines (HGPIN,
CPTX-1532). The data suggest that PCADM-1 and/or
RPS2 might be novel bio-markers and excellent prognos-
tic indicators for human prostate cancer. More impor-
tantly, PCADM-1 or RPS2 might be novel therapeutic
targets for treating the disease.
In this paper, we have examined the importance of the
RPS2 gene for proliferation and survival of malignant and
normal prostate cell lines in vitro and in vivo. We have
developed a 'ribozyme-like' oligonucleotide, DNAZYM-
1P, which specifically targets RPS2 and found that
DNAZYM-1P treatment of PC-3ML, LNCaP, and CPTX-
1532 cells induced a significant increase in cellular apop-
tosis and death (i.e. > 95% after 48 hr). Mouse tumor
modeling studies further revealed that DNAZYM-1P deliv-
ered locally or systemically, eradicated primary and meta-
static tumors of PC-3ML cells in SCID mice. More
importantly, treatment dramatically increased mice dis-
ease free survival rates by 100%. For the first time, we have
convincingly demonstrated that tumors which over
express the RPS2 protein can be eradicated with a
DNAZYM-1P targeting this gene.
Methods
Cell cultures
LNCaP, DU145, CRW22R1 and mouse 3T3 fibroblasts
were obtained from ATCC (Bethesda, MD) and grown
according to their instructions. PC-3 ML cells were main-
tained in DMEM plus 10% fetal bovine serum according
to published methods [5]. CPTX-1532 and NPTX-1532
cells were derived from malignant and normal tissue of
the same human prostate tissue, respectively [6]. BPH-1
cells [7] were a gift from Donna Peehl (Stanford Univ.).
CPTX-1532, NPTX-1532, and BPH-1 cells were each
immortalized with human papillomavirus serotype 16
[8]. IBC-10a [9] cells were primary 'intermediate basal
cell' cultures derived from a Gleason score 6 prostate can-
cers by our lab. IBC-10a cells were subsequently immor-
talized with hTERT (courtesy of Johng Rhim, Bethesda,
MD). The IBC-10a cells were also transfected with a
pBABE-c-myc puromycin vector (courtesy of Dr. Sell,
Drexel Univ., Philadelphia, PA)(the pBABE vector was
purchased from Clonetics Inc., Boston, MA)) and stable
clones selected for 2 weeks with 2 ug/ml puromycin. The
CPTX-1532 and NPTX-1532, BPH-1, and IBC-10a were
maintained at low passage (< 10) in Keratinocyte serum
free media (SFM) (Life Technologies, Inc., Grand Island,
NY) containing 5 ng/mL epidermal growth factor, 50 μg/
mL bovine pituitary extract, plus 100 units/mL penicillin
G sodium and 100 μg/mL streptomycin sulfate. Cells were
cultured at 37°C in a humidified atmosphere of 95% air
and 5% CO2. In experimental studies, the cells were har-
vested using a 1:10 dilution of 10X Trypsin-EDTA (Invit-
rogen, Grand Island, N.Y.) in PBS, pH 7.4 and washed
three times with fresh keratinocyte SFM, counted with a
hemacytometer, and plated in keratinocyte SFM o.n. prior
to starting experimental treatments. Cell growth assays
were carried out using MTS reagents according to methods
of the manufacturer (Promega Inc., Madison, WI).
Recombinant RPS2 protein
The RPS2 cDNA isolated from PC-3ML cells was inserted
into a phagemid ZAP expression vector system using a
protocol described by the manufacturer (Stratagene Inc.,
La Jolla, CA). A pGEXR-GST fusion protein was cloned in
BL21 (DES) pLysS E. coli. The cDNAs from 3 clones was
sequenced by the DNA facility (Univ. of Pennsylvania) to
verify the gene. Recombinant GST-RPS2 protein was puri-
fied using the MagneGST protein purification system
according to a protocol provided by the manufacturer
(Promega Inc.).Journal of Experimental & Clinical Cancer Research 2009, 28:6 http://www.jeccr.com/content/28/1/6
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PCR primers for RPS2
Total RNA (1 μg) was reverse transcribed using the
SUPERSCRIPT™ II Rnase H- Reverse Transcriptase System.
Samples were subjected to PCR amplification in a total
reaction volume of 50 μl containing 10× PCR buffer
(GIBCO BRL®), 50 mM  MgCl2 (GIBCO BRL®), 10 mM
dNTP, 5 pmol concentration of each specific primer, and
2.5 units of Taq DNA polymerase (GIBCO BRL®). The PCR
reaction was carried out in a programmable thermal con-
troller (PTC-100, MJ Research, Inc., Watertown, MA). The
reaction mixture was denatured at 94°C for 3 min fol-
lowed by 30 cycles at 94°C for 45 s, annealing at 60°C for
45 s and 72°C for 1 min. The final elongation was
extended for an additional 20 min. The amplified PCR
products were resolved electrophoretically on agarose gel
stained with ethidium bromide to verify size of the ampli-
fied product [10]. Also, the identity of RPS2 fragments was
verified by nucleotide sequencing (Molecular Sequencing
Facility, Univ. Pennsylvania, Philadelphia, PA).
Forward Primer: 5': GCCAAGCTCTCCATCGTC-3' 18
MER, TM: 59.8
Reverse Primer: 5'-GTGCAGGGATGAGGCGTA-3': 18
MER, TM: 60.6
Melting curve analyses showed a clean primer dimer free
RPS2 DNA peak (90°C). PCR reactions were repeated
twice to confirm the size of the 350b products (30 cycles)
seen on the agarose gels [10]. The Stratagene cDNA was
used as a positive control.
DNAZYM-1P (31b)
The DNAZYM-1P was designed with two flanking 8 base
sequences which recognize the RPS2 mRNA and a 15 base
catalytic domain known as the '10–23' motif as the core.
The DNAZYM-1P was similar in design to the DNZYM
previously developed by others for targeting HIV-1 gag, c-
myc, and egr-1 RNA, respectively [11-14]. (fig. 1S, addi-
tional file 1). A 'scrambled' DNAZYM was made with ran-
dom flanking sequences and the 15 base catalytic domain
(fig. 1S). The sequences for 2 different DNAZYMs are
shown below and include the flanking regions (8 bases)
and catalytic domain (underlined). Note: Both DNAZYM-
1P and 2P exhibited similar potency and only the data
from the DNAZYM-1P is reported in this paper. The






SCID mouse tumor modeling studies
The studies were carried out utilizing 6–8 week old male
CB17-SCID mice (Severe Combined Immunodeficient
Mice, Taconic Labs, Germantown, N.Y.) according to pre-
viously published methods [15]. PC-3 ML tumor cells
were derived from parent PC-3 cells after repeated selec-
tion of the invasive PC-3 cells utilizing Matrigel coated
modified Boyden Invasion Chambers [5] (BD Bio-
sciences, Franklin Lakes, N.J.). Invasive cells were then
injected i.v. in SCID male mice and single cell clones iso-
lated from the bone marrow tumors [5]. Two types of
studies were carried out. First the PC-3ML cells were inoc-
ulated s.c. in the scrotal pouch (0.2 ml at 5 × 106 cells)
prior to initiation of treatment on day 28. Mice were then
treated by localized injection of the DNAZYM-1P (4.0 ug/
1 ml in 0.1 ml biw). Secondly, cells were injected i.v. via
the tail vein (0.2 ml at 1 × 105 cells) twice at 10 day inter-
vals, and once tumors were established, treatment was ini-
tiated day 20. Mice were then treated by i.v. injection via
the tail vein of the DNAZYM-1P (i.e. 4.0 ug/ml in 0.1 ml
weekly). In controls, mice were injected with the scram-
bled DNAZYM or lipofectamine 2000 (vehicle) (Invitro-
gen). Immediately prior to injection, the DNAZYM-1P
resuspended in DMEM was incubated with 20 uM lipo-
fectamine 2000 for 1 hr at room temperature.
Western blots and immunolabeling
SDS PAGE, Western blots and protein measurements were




PCR primers specific for the n-terminal domain of the
RPS2 mRNA revealed that 3 different malignant PCa cell
lines (i.e. LNCaP, PC3-ML, DU145) and 3 pre-malignant
or partially malignant lines (HGPIN, CPTX-1532, pBABE-
IBC-10a-cmyc) over expressed the RPS2 mRNA. The
mRNA (i.e. cDNA after 35 cycles) was barely detectable in
several non-malignant primary cell strains, including
BPH-1, IBC-10a and NPTX-1532 cells, and was not
present in 3T3 fibroblasts (fig. 2S, additional file 1).
Sequencing of the 350b fragments revealed a 100%
homology with the RPS2 mRNA.
Western blot studies
Crude protein extracts (100 mg/ml) from BL21 E. coli con-
taining recombinant pGEXR-GST-RPS2 fusion protein
were incubated with MagneGST Glutathione Particles and
the magnetic beads removed with a magnet. Following
three washes with the binding buffer to remove unbound
protein (fig. 1a, lanes 3–4), GST-RPS2 fusion protein was
recovered by elution with 50 mM glutathione (fig. 1a,
lanes 5–6). Western blots with RPS2 antibodies revealed
that the ~62 Kda GST-RPS2 complex contained RPS2 (fig.Journal of Experimental & Clinical Cancer Research 2009, 28:6 http://www.jeccr.com/content/28/1/6
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1a, lanes 10–11). A lower molecular weight band at 33
Kda was also blotted with the RPS2 antibodies (fig. 1a,
lanes 10–11). Control blots with RPS2 antibody pre-
absorbed with purified rRPS2 protein, failed to blot the
GST-RPS2 protein complex (fig. 1a, lanes 12–16). Blots
with GST antibodies (1:400 dil.) blotted only the 62 Kda
of GST-RPS2 protein complex (not shown). Western blots
of nuclear protein extracts from human prostate cell lines
showed that RPS2 was abundantly expressed in several
malignant prostate cancer cell lines, including: pBABE-
IBC-10a-c-myc (Ir), CPTX-1532 (C), LNCaP(L),
CRW22R1 (CW), and PC-3ML (P) cells, but was not
expressed (or faintly expressed) in normal prostate cell
lines, including two different sub-clones of parent IBC-
10a cells (I), mouse NIH 3T3 fibroblasts, BPH-1, and
NPTX-1532 cells (fig. 1b).
DNAZYM-1P studies
Western blots showed that a DNAZYM-1P designed to tar-
get the n-terminal ATG start site of the RPS2 mRNA pro-
tein 'knocked-down' the detectable levels of nuclear RPS2
protein in PC-3ML cells after 8–48 hr treatment (fig. 2a,
top lane). Controls showed that a DNAZYM-1 with scram-
bled base sequences in the flanking regions of the
DNAZYM (i.e. scrambled oligonucleotide) failed to
'knock-down' RPS2 expression after 0–48 hr (fig. 2a, mid-
dle lane). Densitometry scans of the bands and compari-
sons of the ratio of RPS2/actin showed that the relative
level of RPS2 expression dropped from 1 to 0.5, 0.2, 0.1,
0.05 and < 0.02 following treatment of the PC-3ML cul-
tures with DNAZYM-1P for 0, 8, 12, 24 32 and 48 hr,
respectively (fig. 2b). RT-PCR assays with primers specific
for RPS2 confirmed that the 2 and 4 ug/ml DNAZYM-1P
'knocked-down' expression of RPS2 mRNA after 8 hr in
PC-3ML (P), LNCaP (L), pBABE-IBC-10a-c-myc (IR) and
CRW22R1 (C) cells. The fold expression of RPS2 mRNA in
the 4 different cell lines was normalized to 18S RNA and
then the fold expression calculated relative to RPS2 mRNA
levels in untreated NPTX-1532 cells (value set at 1) (fig.
2c). The scrambled oligonucleotide failed to significantly
alter RPS2 mRNA levels in any of the cell lines, however
(fig. 2c).
Immunoflourescent labeling studies with RPS2 antibod-
ies (i.e. P1 antibodies) revealed that RPS2 was over
expressed in nuclear and cytoplasmic regions of untreated
PC-3ML and CPTX-1532 cells (fig. 3). Figure 3 showed
that following exposure of these cells to DNAZYM-1P (4
ug/ml) for 0 and 4 hr, the cells expressed an abundance of
RPS2 (fig. 3). However, following extended treatments of
24 hr, the majority of the cells were negative for RPS2.
Control experiments showed that PC-3ML cells exposed
to the scrambled DNAZYM oligonucleotide expressed
RPS2 after 0, 4 and 24 hr. In comparison, NPTX-1532 cells
which did not express RPS2, were unaffected by
DNAZYM-1P for 0, 4 and 24 hr (fig. 3). IBC-10a parent
cells also did not express RPS2 or respond to DNAZYM-1P
treatment (data not shown).
Growth assays measured by the MTS assay [8] further
showed that 4 and 6 ug/ml DNAZYM-1P blocked growth
of 3 different malignant prostate cancer lines which over
expressed RPS2, including PC-3ML (P:Z1, P:Z2), CPTX-
1532 (C:Z1) and LNCaP (L:Z1) cells. In comparison, the
scrambled oligonucleotide (P:scr) and lipofectamine
(P:lip) alone did not block growth of PC-3ML cells.
DNAZYM-1P treatment of NPTX-1532 (N:Z2) cells did
not block cell proliferation (fig. 4a). Apoptosis Assays
using Annexin V antibody labeling and flow cytometry
showed that 4 & 6 ug/ml DNAZYM-1P induced increased
amounts of apoptosis in PC-3ML cells after 8–24 hr (i.e.
5% to 28%) (fig. 4b, ■, ), but failed to induce significant
a (Lanes 1–6) SDS PAGE of (lane 1) mwt markers; (lane 2)  crude bacterial cell lysate containing the GST-RPS2 fusion  protein; (lanes 3–4) unbound proteins; (lanes 5–6) GST-RPS2  fusion protein bound to the MagneGST Glutathione Particles;  (lanes 7–11) RPS2 antibody (1:1000 dil.) Western blots of  proteins in lane 2, 3, 4, 5, and 6, respectively Figure 1
a (Lanes 1–6) SDS PAGE of (lane 1) mwt markers; 
(lane 2) crude bacterial cell lysate containing the 
GST-RPS2 fusion protein; (lanes 3–4) unbound pro-
teins; (lanes 5–6) GST-RPS2 fusion protein bound to 
the MagneGST Glutathione Particles; (lanes 7–11) 
RPS2 antibody (1:1000 dil.) Western blots of proteins 
in lane 2, 3, 4, 5, and 6, respectively. (lanes 12–13) 
Western blots of fractions in lanes 5–6 following preabsorp-
tion of the P1 antibodies (1:200 dil.) with excess recombinant 
RPS2 (200 ng). Note: the P1 antibodies blotted 2 different 
bands of the GST-RPS2 complex at ~62 Kda plus the 33 Kda 
RPS2 protein. 1b. Western blots with RPS2 antibodies 
(1:1000 dil.) of nuclear protein extracts from: (Ir) pBABE-
IBC-10a-c-myc; (I) 2 different IBC-10a sub-clones; (M) mouse 
NIH-3T3; (B) BPH-1, (N) NPTX-1532, (C) CPTX-1532, (L) 
LNCaP, (CW) CRW22R1, and (P) PC-3ML cells. Lower 
bands: actin antibody blots of nuclear extracts. Loaded at 20 
ug/lane.Journal of Experimental & Clinical Cancer Research 2009, 28:6 http://www.jeccr.com/content/28/1/6
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amounts of apoptosis in NPTX-1532 cells after 0, 8, 24, 48
and 72 hr treatment (i.e. < 1.2%)(fig. 4c, ■, ). Control
studies confirmed that lipofectamine (▲) alone or the
scrambled DNAZYM oligonucleotide (❍), and vehicle ()
failed to induce apoptosis in either PC-3ML (fig. 4b) or
NPTX-1532 (fig. 4c) cells. In other studies, pBABE-IBC-
10a:c-myc cells which over expressed RPS2 exhibited high
levels of apoptosis of 9% and 30% by 8 and 24 hr in
response to 6 ug/ml DNAZYM-1P (data not shown).
SCID mice tumor modeling studies
Tumor modeling studies were carried where PC-3ML
tumor cells were injected in the scotal sac of 8 week old
SCID mice. Since the testis do not descend by 8–14 weeks
of age, it was possible to inject in the scotal sac where the
bulk of the cells or reagent tend to remain following injec-
tion. We allowed the tumors to establish and reach a size
that was palpable after 28 days prior to initiating treat-
ment with the DNAZYM-1P. Mice were then treated for ~2
mos at a dosage of 4 ug/biw injected topically in the scrotal
sac. In mice treated with 4 ug/ml biw DNAZYM-1P (▲)(n
= 50), 33/50 mice exhibited no detectable tumors and 12/
50 had tiny nodules (< 0.2 cm3) which were hollow
spheres coated by collagen networks and empty of tumor
cells. In untreated mice (❍) (n = 20) or mice treated with
the scrambled oligonucleotide ()(n = 30) or vehicle (n
= 20) () the tumors reached a size of 2–2.6 cm3 after ~2
mos and all the mice had scrotal sac tumors plus localized
metastases to the peritoneal cavity (fig. 5a). None of the
mice exhibited detectable metastases (fig. 5a).
Similar studies were then carried out to assess whether
DNAZYM-1P delivered systemically, could block the
growth of tumors disseminated to a variety of organ sys-
tems. In these experiments, mice were injected i.v. via the
tail vein at day 1 and day 10 with 1 × 105 cells/ml then
treatment started after 2 weeks by i.v. injection via the tail
vein of DNAZYM-1P (▲)(n = 30), scrambled oligonucle-
otide ()(n = 30), vehicle (❍)(n = 30), or buffer ()(n =
30). The data in fig. 5b showed that tumors did not sur-
vive in mice treated with DNAZYM-1P (▲), whereas
numerous tumors were found in the kidney, sternum, per-
Figure 2
a Western blots with RPS2 antibodies of crude cell extracts  from PC-3ML cells following treatment with (top lane) 20 nM  DNAZYM-1P for increased times of (lanes 1–6) 0, 8, 12, 24,  32 and 48 hr, respectively Figure 2
a Western blots with RPS2 antibodies of crude cell 
extracts from PC-3ML cells following treatment with 
(top lane) 20 nM DNAZYM-1P for increased times of 
(lanes 1–6) 0, 8, 12, 24, 32 and 48 hr, respectively. 
Control cells were treated for identical times with (middle 
lane) 20 nM scrambled oligonucleotide. (bottom lane) beta 
actin antibody blots. 2b. Comparisons of the ratio of RPS2/
actin from densitometry scans of the Western blots in fig. 2a. 
2c. RT-PCR assays showing the relative level of RPS2 expres-
sion in (P) PC-3ML; (L) LNCaP; (IR) pBABE-IBC-10a-c-myc; 
and (C) CPTX-1532 cells (at 90% confluent) which were () 
untreated or treated with () scrambled oligonucleotide, and 
() 2 and (■) 4 ug/ml DNAZYM-1P for 8 hr. Shows that the 
DNAZYM-1P knocks out RPS2 mRNA expression in all 4 
cell lines. (×) NPTX-1532 express low levels of RPS2 mRNA 
(value set at 1). RT-PCR vales were normalized relative to 
18S RNA, and then the fold expression calculated relative to 
values for untreated NPTX-1532 cells which were set at 1. 
Results averaged from 3 experiments +/-1 S.D.Journal of Experimental & Clinical Cancer Research 2009, 28:6 http://www.jeccr.com/content/28/1/6
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itoneum, liver and lungs of mice treated with scrambled
oligonucleotide (), vehicle (❍) or buffer ().
Mouse survival studies were then carried out under the
conditions described in fig. 5b, where treatment with the
different agents was discontinued after 2 mos and the
mice monitored for ~4 mos. The mouse survival data
showed that the mice all died by ~7–15 weeks in mice
treated with lipofectamine (▲) or scrambled oligonucle-
otide () (fig. 5c). In mice treated with 2, 3 and 4 ug/ml
Immunolabeling of PC-3ML, CPTX-1532 and NPTX-1532 cells with RPS2 antibodies following treatment with 4 ug/ml  DNAZYM-1P or scrambled oligonucleotide for 0, 4 and 24 hr Figure 3
Immunolabeling of PC-3ML, CPTX-1532 and NPTX-1532 cells with RPS2 antibodies following treatment with 
4 ug/ml DNAZYM-1P or scrambled oligonucleotide for 0, 4 and 24 hr. Cells were labeled with RPS2 P1 antibody 
(1:200 dil.) and Alexoflour secondary antibodies counterstained with DAPI. Cells were at ~70% confluence at the time treat-
ment was initiated.Journal of Experimental & Clinical Cancer Research 2009, 28:6 http://www.jeccr.com/content/28/1/6
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DNAZYM-1P, mouse survival was either (●) 40%, (■)
90% and () 100%, respectively. H&E stained sections
and RPS2 antibody labeled sections of the tiny tumors
present at the time treatment was initiated, showed that
the PC-3ML cells normally formed solid tumor masses
and the cells over expressed RPS2. In mice treated with the
scrambled oligonucleotide for 2–3 mos, the tumors still
consisted of a packed mass of PC-3ML cells (fig. 5d)
which expressed RPS2 (fig. 5e). Residual nodules some-
times remained following treatment of the mice with
DNAZYM-1P for 2 mos. These nodules consisted of a col-
lagen shell, but were largely empty masses filled with
debris that was not immunolabeled with RPS2 antibodies
(data not shown). Overall, we found that DNAZYM-1P
treatment of the mice appeared to be of low or zero toxic-
ity to the mice since they gained weight on a regular basis,
were robust and healthy in appearance and showed zero
neuropathy or hair loss. Histology of the liver, kidney,
spleen, brain, spine, lungs, and heart indicated normal
undamaged tissue. Also the growth of fibroblast cultures
from the prostate tissue of mice was not hindered by 4 and
6 ug/ml DNAZYM-1P, indicating the DNAZYM-1P proba-
bly does not target cells which express low levels of RPS2
protein.
Discussion
Earlier immunolabeling studies with polyclonal antibod-
ies had revealed that the RPS2 antigen was over-expressed
in 100% of prostate cancer luminal epithelial cells (n = 20
prostates examined). In contrast, the protein was not
expressed in NPTX-1532, benign prostate hyperplasia
(BPH), seminal vesicle (SV) or in skeletal or smooth mus-
cle tissues from the same prostates with (or without) can-
cer foci [1]. Likewise, RPS2 (aka: PCADM-1) was not
expressed by primary prostate tissue fibroblast cultures,
WI38 human fibroblasts, human peripheral blood lym-
phocytes or human hepatocyte cultures [1].
In this paper, we have examined whether the PCADM-1
gene/protein is normally over expressed in malignant
prostate cancer. Western blots indicated benign prostate
did not express the protein, whereas malignant prostate
cancer expressed PCADM-1 and the amount of RPS2
expressed increased with the tumor grade. We have, there-
fore, focused on studies designed to test whether RPS2
over expression in prostate cancer cell lines is essential for
cell survival. To our surprise, we found in 'anti-sense'
knock-out experiments with a DNAZYM-1P which tar-
geted the RPS2 mRNA, that gene expression was essential
for cell survival, but only in cells which over expressed the
RPS2 protein (i.e. in PC-3 ML, LNCaP, CPTX-1532 and
pBABE-IBC-10a-c-myc cells). In comparison, prostate cell
lines expressing very little RPS2 (i.e. BPH-1, NPTX-1532
or IBC-10a cells) were not affected by the DNAZYM-1P
treatment even at high concentrations for prolonged
intervals. That is, only the PC-3ML and pBABE- IBC-10a-
c-myc cells which expressed elevated RPS2 underwent
apoptosis and failed to grow in response to DNAZYM-1P.
NPTX-1532 or IBC-10a cells which failed to express
detectable RPS2 did not undergo apoptosis. Likewise,
DNAZYM-1P treatment of localized or metastatic tumors
in SCID mice, completely eradicated the tumors, but did
not inflict noticeable harm to normal mouse cells. We
interpret this to mean that the over-expression of RPS2
might promote ribosomal biogenesis and growth of
tumor cells and that the tumor cells acquire a dependence
on RPS2 for survival. Thus, 'knock-out' of RPS2 results in
a 'shut-down' of ribosomal biogenesis and a cascade of
apoptotic events leading to inhibition of cell growth and
apoptosis. Again, a similar response was not observed in
normal cells since the temporary 'knock-down' of RPS2
mRNA had little impact on overall cell homeostasis.
Perhaps more importantly, we found that DNAZYM-1P
treatment of tumor bearing mice was a highly effective
therapeutic approach to eradicating tumors and dramati-
cally improving disease free mouse survival rates. We
showed that the DNAZYM-1P eliminated PC-3ML tumors
in mice (> 90%) and that treatment resulted in a signifi-
cant increase in disease free mouse survival rates (> 80–
100%) after discontinuation of the treatment for ~4 mos.
The DNAZYM-1P was non-toxic after prolonged treat-
ment intervals and following the discontinuation of treat-
ment, tumor recurrence was not detected in the liver,
lungs, peritoneum or other organs after several months
indicating the mice were cured of cancer. The implication
a MTS assays showing that 4 or 6 ug/ml DNAZYM-1P (i.e. Z1 and Z2, respectively) treatment of 90% confluent cultures not  only blocked cell growth, but reduced the cell density after 8, 24 and 48 hr, respectively, in (P:Z1, P:Z2) PC-3ML, (L:Z1)  LNCaP, and (C:Z1) CPTX-1532 cells Figure 4 (see previous page)
a MTS assays showing that 4 or 6 ug/ml DNAZYM-1P (i.e. Z1 and Z2, respectively) treatment of 90% confluent 
cultures not only blocked cell growth, but reduced the cell density after 8, 24 and 48 hr, respectively, in (P:Z1, 
P:Z2) PC-3ML, (L:Z1) LNCaP, and (C:Z1) CPTX-1532 cells. The growth of (N:Z2) NPTX-1532 cells was not blocked 
by 6 ug/ml DNAZYM-1P treatment after 0, 8, 24 and 48 hr, however. Controls showed that growth of PC-3ML cells treated 
with lipofectamine (P:lip) or a 6 ug/ml scrambled DNAZYM oligonucleotide (P:scr) was not blocked. 4b-4c. Apoptosis Assays 
using annexin V antibody labeling and flow cytometry. Showed that 4 & 6 ug/ml DNAZYM-1P (■, ) induced increased 
amounts of apoptosis in (fig. 4b) PC-3 ML cells after 8–24 hr (i.e. 5% to 28%), but failed to induce apoptosis in (fig. 4c) NPTX-
1532 cells after 0, 8, 24, 48 and 72 hr treatment (i.e. < 1.2%). Controls showed that (▲) lipofectamine, (❍) scrambled 
DNAZYM oligonucleotide, or () untreated cells exhibited very low levels of apoptosis.Journal of Experimental & Clinical Cancer Research 2009, 28:6 http://www.jeccr.com/content/28/1/6
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Figure 5 (see legend on next page)Journal of Experimental & Clinical Cancer Research 2009, 28:6 http://www.jeccr.com/content/28/1/6
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is that targeting RPS2 in prostate cancer might be an excel-
lent therapeutic strategy.
A number of studies have previously shown that the over
expression of different ribosomal proteins might play an
important role in cancer. Chiao et al. [16] has shown that
RPS2 ribosomal mRNA was over expressed in head and
neck cancer and barely detectable in normal tissue. Others
have found that the rat ribosomal protein S3a is identical
to rat v-fos transformation effector protein [17]. Karan et
al. [18] found 34 genes are up-regulated and eight genes
are down-regulated in androgen-independent prostate
cancer cells, including L10 (RPL10), L32 (RPL32), and
S16 (RPS16). It therefore appears that independent, non-
coordinate changes in expression of a subset of ribosomal
proteins, might occur which have no direct association or
correlation with proliferative and/or protein synthetic
activities involved in ribosomal biogenesis [4,19,20], but
could be involved in transformation [21,22]. For exam-
ple, studies by Naora et al. [22] showed that enhancement
of RPS3a expression in NIH 3T3 cells induced transforma-
tion and formation of tumors in nude mice and they
found that S3a expression was a critical gene for tumor
cell survival and tumorigenesis.
Like S3a, our data suggested that over expression of RPS2
was associated with prostate tumor formation and key for
tumor cell survival. The interesting aspect of these studies
is that suppression of enhanced RPS3a or RPS2 expression
both could be associated with and/or involved in a down-
stream pathway which leads to apoptosis. For example, S-
12 cells that over express RPS3a, undergo apoptosis when
enhanced RPS3a expression was inhibited [22].
There is some precedent for this suggestion. There are
cases where growth inhibition and/or apoptosis have
been induced by switching off expression of c-myc and bcr-
abl in promyelocytic, and in chronic myeloid, leukemia
cells, respectively [23,24]. Thus, it is possible that apop-
totic induction might arise as a default event when RPS3a
or RPS2 expression is blocked, simply from an inadvertent
inhibition of survival factors. Unfortunately, the physio-
logical signals that mediate such suppression are probably
cell specific and obviously remain to be elucidated.
As pointed out in the introduction, there are many reports
showing a connection between over-expression of genes
encoding ribosomal proteins and cancer [16,17,25-32].
The implication is that these ribosomal proteins have
additional functions distinct from their role as ribosomal
proteins regulating protein synthesis [16,17,25-32]. In
this respect, specific 'leucine zipper' sequence motifs are
characteristic of numerous ribosomal proteins which
allow binding to nucleic acids [16,17,26,29-31] and a
possible role in regulating transcriptional and transla-
tional mechanisms. For example, the rat ribosomal pro-
tein S3a is identical to the product of the rat v-fos
transformation effector gene [29]. And S3a is normally
involved in initiation of protein synthesis and is related to
proteins involved in the regulation of growth and the cell
cycle [4]. In one study, over expression of S3a was able to
induce transformation of NIH 3T3 cells and induce for-
mation of tumors in nude mice [33]. But the ability of S3a
to induce transformation was dependent on its role in
suppressing programmed cell death [33]. A second exam-
ple is the rat ribosomal protein L10. L10 is homologous
to a DNA-binding protein and to a putative Wilm's tumor
suppressor gene [28]. A third example is S19 where a
mutation in the S19 ribosomal protein has been associ-
ated with a predisposition to cancer in patients with Dia-
mond-Blackfan anaemia [34]. Finally, RPS2 was shown
by our lab to specifically bind a classical 'break point clus-
ter region' sequence found in leukemia [35], implicating
RPS2 as a DNA binding protein. The DNA binding
domain is a leucine zipper domain where 4 point muta-
tions have been detected. Thus, aberrant over expression
of RPS2 or the mutant form of RPS2 (termed PCADM-1)
might somehow activate oncogenes involved in tumor
development. In this connection, the individual and/or
combined effects of a variety of ribosomal proteins (i.e.
like RPS2, S3a, L10, and L19) might directly control gene
a Mice were injected in the scrotal sac with 1 × 106 PC-3ML cells Figure 5 (see previous page)
a Mice were injected in the scrotal sac with 1 × 106 PC-3ML cells. Treatment was initiated at day 28, and mice treated 
with (▲) 4 ug/biw DNAZYM-1P) (n = 50); () scrambled oligonucleotide (n = 30); () vehicle (n = 20) or (❍) untreated. The 
agent was injected in the scotal sac in 0.1 ml buffer. Tumor size was measured with calipers at 2 week intervals. 5b. Mice (n = 
30/agent) were injected i.v. via the tail vein at day 1 and day 10 with 1 × 105 cells/ml (in 0.1 ml) then treatment started after 2 
weeks by i.v. injection via the tail vein weekly of () scrambled oligonucleotide, (❍) vehicle, () buffer, and (▲) DNAZYM-1P. 
Tumor volume was measured in 2 mice at 2 weeks by sacrificing a few mice for measurements and then at the time of sacrifice 
following treatment of mice for 1, 2, 3 and 4 mos. 5c. Mice were injected with tumor cells according to methods in fig. 5b and 
treated with either () 4 ug/ml, (■) 3 ug/ml and (●) 2 ug/ml biw DNAZYM-1P. Control mice were treated with (▲) lipofectamine 
and () scrambled oligonucleotide. Mice were treated for 2 mos, then treatment was discontinued for up to 17 weeks. 5d–5e. 
H&E and RPS2 antibody immunolabeled sections of a tumor from a mouse treated with the scrambled oligonucleotide for 2 
mos (see fig. 5c).Journal of Experimental & Clinical Cancer Research 2009, 28:6 http://www.jeccr.com/content/28/1/6
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expression patterns, oncogene expression and transforma-
tion.
Conclusion
We believe that targeting one or more of these ribosomal
proteins (i.e. RPS2 or S3a) may lead to development of a
highly effective treatment for prevention of cancer, eradi-
cation or primary tumors or a blockade of tumor metasta-
sis.
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